

HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

HEREDITARY ANGIOEDEMA AGENTS

Berinert®, Cinryze®, icatibant, Firazyr®, Haegarda®, Kalbitor®, Takhzyro®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

| | | |
|---------------|--------------|-----------------|
| Date: | Member Name: | ID#: |
| DOB: | Gender: | Physician: |
| Office Phone: | Office Fax: | Office Contact: |

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: ☐ Berinert® (C1 esterase inhibitor [human])* , ☐ Haegarda® (C1 esterase inhibitor [human]), ☐ icatibant

Non-preferred: : ☐ Cinryze® (C1 esterase inhibitor subcutaneous [human]) ☐ Firazyr® (icatibant), ☐ Kalbitor® (ecallantide), ☐ Takhzyro® (lanadelumab)

*preferred for specified populations. Refer to medication use policy.

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

| Questions | Yes | No | Comments/Notes |
|---|--------------------------|--------------------------|-------------------------------------|
| 1. Is the request for treatment of Hereditary Angioedema (HAE)? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Is the requesting provider a board-certified immunologist or allergist? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. Does the member have clinical presentations consistent with a HAE subtype (HAE I, HAE II, or HAE with normal C1INH) confirmed by repeat blood testing? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 4. Has the member's diagnosis of Hereditary Angioedema been confirmed with complement 4 (C4) protein and C1-inhibitor levels? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 5. Has the member had a trial and failure of each of the following: antihistamines, glucocorticoids, and epinephrine? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 6. Is the member currently taking ACE-inhibitors or estrogen-containing oral medications? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 7. Has the member's attack frequency, severity, and location been documented? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 8. Is the member/caregiver able and ready to administer medication at home? | <input type="checkbox"/> | <input type="checkbox"/> | |

| | | | |
|---|--------------------------|--------------------------|-------------------------------------|
| 9. For acute HAE attack treatment: Does the member have a history of at least one attack per year? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 10. For long-term prophylaxis of HAE attacks: Does the member have a history of two acute severe attacks per month or at least 5 attacks of moderate severity per month on average? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 11. For long-term prophylaxis of HAE attacks: Has the member tried and failed, or have a contraindication to, danazol therapy? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 12. For long-term prophylaxis of HAE attacks: Does laboratory test show the member has not experienced HAE attacks due to preventable triggers, such as helicobacter pylori infections in members with gastrointestinal attacks? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| REAUTHORIZATION | | | |
| 1. Is the request for reauthorization of therapy? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 2. Has the member experienced unacceptable toxicity (e.g. hypersensitivity reactions, serious thrombotic events, significantly elevated hepatic serum transaminases) to the drug? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 3. For acute HAE attack treatment: Does documentation show that the member continues to experience at least one acute HAE attack per year AND is the request for a refill due to a documented attack OR has the medication on hand reached the expiration date? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| 4. For long-term prophylaxis of HAE attacks: Has the provider evaluated the member's need for long-term prophylaxis at least once per year? | <input type="checkbox"/> | <input type="checkbox"/> | |
| 5. For long-term prophylaxis of HAE attacks: Has the member had significant improvements in severity and duration of attacks compared to baseline? | <input type="checkbox"/> | <input type="checkbox"/> | Please provide documentation |
| What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. | | | |
| Additional information: | | | |
| Physician's Signature: | | | |

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-031
 Origination Date: 07/01/2024
 Reviewed/Revised Date: 11/13/2024
 Next Review Date: 11/13/2025
 Current Effective Date: 12/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.